U

Our purpose

To improve life during and beyond sedation

Sedana Medical is a pioneer medtech and pharmaceutical company dedicated to making inhaled sedation a standard therapy in intensive care.

Bringing inhaled sedation to intensive care

We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.

Through the results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD*, we have laid the foundation for inhaled sedation in intensive care.

By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.

*formerly known as AnaConDa

Learn more

Sedana Medical Clinical Development Program

We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.

Through the results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD*, we have laid the foundation for inhaled sedation in intensive care.

By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.

*formerly known as AnaConDa

Learn more

Sedaconda ACD

Sedaconda ACD (Anaesthetic Conserving Device) is a medical device enabling delivery of inhaled sedation to invasively ventilated patients.

Learn more

Using Sedaconda ACD

Improve your knowledge about our products with our Training Material and Frequently Asked Questions.

Learn more

Our Products

Explore our broad portfolio of products for the administration of inhaled sedation.

Learn more
acd

Sedaconda ACD-S

acd

Sedaconda ACD Starter Kit

Adapter

Adapters

Scavenging-Flurabsorb

Scavenging / Flurabsorb

Bistos-Gas-montior

AMG-06 Gas Monitor

Press Releases

2026

Sedana Medical reports first patient treated in Early Access Program in the U.S.
2026-03-13 08:00
Sedana Medical AB (publ) today reports that the first patient has been treated in the company’s Early Access Program (EAP) in the U.S. The program...
Sedana Medical AB’s Year-end report 2025
2026-02-12 07:00
Regulatory MAR
Positive EBITDA in our ex-US business Fourth quarter 2025 January-December 2025 CEO comments Positive EBITDA in our ex-US business 2025 marked a successful...
See More

Financial Calendar

See More